Introduction & Meeting Objectives
Co-chairs: David Maloney & Sarah Nikiforow

Session 1:  Emerging CARs and future challenges in solid tumors
Chairs: David Maloney & Maria Pia Morelli 

• New solid tumor targets and engineering strategies for CAR-T: Justus Weber
• Sleeping Beauty Therapy TCR-T Therapy in solid tumors: Maria Pia Morelli
• Understanding mechanisms of immune resistance and developing strategies to overcome them: Smita Chandran

Panel discussion

Keynote talk: Review of results from CAR-T and TCRs in solid tumors: Julian Molina

Panel discussion

Session 2: Head & neck/brain tumors
Chairs: Kedar Kirtane & Susanne Baumeister

• Updates in cellular immunotherapy for head & neck cancers: Kedar Kirtane
• ALK-CAR T-cells for R/R neuroblastoma: Susanne Baumeister
• GD2-CART01 for R/R high-risk neuroblastoma: Francesca del Bufalo
• TanCART, novel CAR T-cell that simultaneously targets EGFRvIII and IL-13Rα2: Bryan Choi

Panel discussion

Break

Session 3: CAR-T clinical advances in lung cancer
Chairs:  Prasad Adusumilli & Julian Molina

• Updates on TIL therapy in lung cancer: Ben Creelan
• Tumor immune modulation in solid tumor CAR T-cell therapy: Prasad Adusumilli
• LL3-directed CAR T-cells in small-cell lung cancer: Adam Schoenfeld

Panel discussion

Session 4: Breast cancer and ovarian cancer
Chairs: Jennifer Specht & Smita Chandran

• LYL797 in adults with solid tumors: Jennifer Specht
• TCR-based therapeutics that target an elite class of common and shared tumor targets called ‘public neoantigens’: Smita Chandran
• Intratumoral Delivery of Dendritic Cell-based Immunotherapies: Potential to Unlock Systemic anti-tumor Response in Breast Cancer: Saurabh Garg
• Engineering NK cells for ovarian cancer: Rizwan Romee

Panel discussion

Lunch

Session 5: Melanoma and sarcomas
Chairs: Amod Sarnaik & Allison Betof Warner 

• Autologous tumor infiltrating lymphocytes, in the treatment of patients with metastatic melanoma (LN-144): Amod Sarnaik
• TIL therapy for melanoma – have we reached the tip of the Iceberg?: Allison Betof Warner
• Afamitresgene Autoleucel in advanced synovial sarcoma and myxoid/round cell liposarcoma: Elizabeth Loggers

Panel discussion

Session 6: Logistics and manufacturing
Chairs: David Maloney & Sarah Nikiforow

• Manufacturing/FACT and ASTCT 80/20: Sarah Nikiforow
• Biomarker-driven trials: William Go

Panel discussion

Break

Keynote talk: An FDA perspective on CAR-T/cellular therapies in cancer: Asha Das

Panel discussion

Session 7: Gastrointestinal cancers
Chairs: Diane Simeone & Joel Randolph Hecht

• CAR-T advances in pancreatic cancer: Diane Simeone
• Autologous TAC T-cells targeting solid tumors, HER2 and Claudin18.2: Benjamin Schlechter
• T-cell therapy for GI tumors: Joel Randolph Hecht

Panel discussion

Session 8: Genitourinary cancers
Chairs: Vivek Narayan & TBC

• Bispecific antibodies and CAR-T approaches in metastatic castration-resistant prostate cancer: Vivek Narayan
• Advancing engineered T-cell therapies for solid tumors: Saul Priceman
• TILs treatment in bladder cancers: Michael Poch

Panel discussion

Conclusions & end of Day 1

Welcome reception

Welcome
Co-chairs: John Gribben & David Maloney

Session 9: Scientific challenges and new approaches
Chairs: TBC

• CD83 as a target for hematologic malignancies: Marco Davila
• Towards in vivo manufacturing of CAR-T – updates and perspectives: Saar Gill

Panel discussion

Session 10: Long term toxicities of CAR T-cell therapy
Chairs: TBC

• Hematologic toxicity (“ICAHT”): Kai Rejeski
• Evolving neuro-toxicities and new treatment approaches: Bianca Santomasso
• Secondary malignancies: Saurabh Dahiya
• Cause of non-relapse mortality following Auto HCT, CAR19 or T-cell engagers: David Miklos
• New data on TCL after CAR-T: David Hamilton

Panel discussion

 

Break

Session 11: Access and Point of Care in Pediatric Cancer
Chairs: Rebecca Gardner & Shannon Maude

• Accelerating pediatric CAR T-cell progress – decentralized academic manufacturing for expanded access: Claudia Rössig
• CAR-pooling – innovative strategies in pediatric CAR T-cell development: Nirali Shah

Keynote talk: An FDA perspective on CAR-T/cellular therapies in blood cancers: Robert Sokolic

Panel discussion

Session 12: CAR-T in CLL
Chairs: Tanya Siddiqi & David Maloney

• Update on TRANSCEND – liso-cel in CLL/SLL: Tanya Siddiqi
• Mechanisms of resistance to CAR T-cells in CLL: Saar Gill

Panel discussion

Lunch

Session 13: Allo approaches
Chairs: Caron Jacobson & Sattva Neelapu

• Next-gen allo approaches/ donor T-cell cloaking to avoid host rejection: Sattva Neelapu
• Updates for ALLO-647/501 in r/r large B-cell and follicular lymphomas: Frederick Locke
• Updates for Allo CAR-T PBCAR0191: Bijal Shah
• CRISPR-edited allogeneic anti-CD19 CAR T-cell therapy for R/​R B-cell NHL: Loretta Nastoupil
• Allogeneic CAR-NK cells in adults with AML or MDS: May Daher
• iPSC-derived CAR-NK: Krish Patel

Panel discussion

Session 14: CAR-T in ALL
Chairs: Noelle Frey & Bijal Shah

• Brexucabtagene autoleucel for adult ALL: Bijal Shah
• Obe-cel updates and future directions: Claire Roddie
• Dual-targeting with CAR-Ts: Regina Myers
• Anti-CD7 Allogeneic CAR T-cells in Relapsed or Refractory (R/R) T-cell T-ALL/LBL: Shannon Maude
• SCRI-CAR19 with CD19 T-APC to prolong CAR T-cell persistence: Rebecca Gardner

Panel discussion

Break

Session 15: CAR-T in multiple myeloma
Chairs: Yi Lin & Krina Patel

How are T-cell-directed therapies performing in the real world?

• CAR-T: Doris Hansen
• BsAb: Yi Lin

Panel discussion: Susan Bal, Larry Anderson

Race to the front-line

• CAR-T: Krina Patel
• BsAb: Larry Anderson

Panel discussion: Sridevi Rajeeve, Damien Green

Session 16: CAR-T in multiple myeloma continued

Mechanisms of resistance

• CAR-T: Damien Green
• BsAb: Adam Sperling

Panel discussion: Matthew Frigault

Session 17: Novel CAR-T/next-gen BsAb
Chairs: Yi Lin & Krina Patel 

• BCMA-directed CAR T-cell therapy anitocabtagene autoleucel: Matthew Frigault
• BCMA/CD19 FastCART: Juan Du
• Updates for GPRC5D CARs in multiple myeloma: Susan Bal
• New BsAb research and opportunities in myeloma: Sridevi Rajeeve
• Tri-specific T-cell activating construct (TriTAC) targeting BCMA for R/R myeloma: Sumit Madan

Panel discussion

Conclusions & end of Day 2

Faculty Dinner

Welcome

Session 18: Special Sessions – CAR T-cells for autoimmune diseases
Chairs: David Porter & TBC

• Advances in CAR-T for Auto-immune Diseases: David Porter
• YTB323 in severe, refractory systemic lupus erythematosus: Pere Barba
• NK cells engineered to target CD19 Programme in autoimmune diseases: David Shook
• Anti-CD19 CAR T-cell therapy (KYV-101), in Subjects With Refractory Generalized Myasthenia Gravis: Jeremias Motte
• CAR-Tregs for autoimmunity: Matteo Doglio

Panel discussion

Session 19: Expanding the CAR platform for NHL
Chairs: Loretta Nastoupil & Caron Jacobson

• Long-term lymphoma outcomes following CAR T-cell therapy – where are we?: Michael Jain
• ZUMA 22 and ZUMA 23 axi-cel updates: Caron Jacobson
• New data in Liso cel – FL/MZL and MCL: Jeremy Abramson
• QoL – late effects – why are our patients dying?: David Maloney

Panel discussion

Break

Session 20: Bispecifics
Chairs: Loretta Nastoupil & Caron Jacobson

• RWD and trials in progress for Epcoritamab: Krish Patel
• Glofitamab RWD and trials in progress: Tycel Phillips
• Total therapy for LBCL combining Mosun/Pola/Axi-cel: Jay Spiegel
• Optimizing treatment through BsAbs sequencing: Gloria Iacoboni

Panel discussion

Session 21: Next generation CARs for lymphoma
Chairs: Loretta Nastoupil & Caron Jacobson                                                                                                                                                      

• CRG-022, CD22 CAR T-cell therapy for R/R LBCL after CD19 CAR-T: Caron Jacobson
• Bispecific CAR20.19 T-cells in MCL: Nirav Shah
• CD20-targeted auto CAR-T for follicular lymphoma: Mazyar Shadman

Panel discussion

Working lunch

Session 22: CAR-T in AML
Chairs: Saar Gill & David Sallman                                                                                                                         

• AML targets/translational updates: Fabiana Perna
• Current status of CAR-T therapies in AML/MDS: David Sallman
• Mechanism of resistance in AML: Anand Bhagwat
• CAR-T in pediatric AML: Nirali Shah
• Optimizing and future directions with CAR-T/NK therapies in AML: Naval Daver

Panel discussion

Conclusions and end of meeting